Everest Organics Ltd.
Snapshot View

342.50 +4.50 ▲1.3%

26 July 2021, 04:00:00 P.M.
Volume: 8,551

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.everestorganicsltd.com
Financial Indicators
Market Cap 269.84 Cr.
Earnings per share (EPS) 17.14 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 19.67 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 58.22 Trailing Twelve Months Ending 2021-03
Price to Book Value 5.79 Calculated using Price: 337.30
Dividend Yield 0.30 Period Ending 2020-03
No. of Shares Subscribed 0.80 Cr. 8,000,000 Shares
FaceValue 10
Company Profile

Everest Organics carry the business of manufacturing of bulk drugs viz. Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Benzimadizole, etc., having its factory at Sadasivpet Medak District Hyderabad. The construction activities have started in the year 1994 and the commercial production of the company has started in 1996. The company is one of the Major Manufacturers & Exporters of Active Pharmaceutical Ingredients and its intermediates in India. It is an ISO 9001-2008 certified company.

Business area of the company

The company’s facilities comply to GMP standards and is certified by the Drug Control Authority of the Government of Andhra Pradesh, India. It supply products to major multinational companies abroad, prominent well established formulation companies in India, Europe, USA, Far East and the Middle East, and also to Latin / Central / South American Countries. The company also provides adequate technical & documentary support for their products and its products comply to various pharmacopial standards like BP, USP, EP and IP Standards as desired by the customer.

Products

  • Pantoprazole Sodium Sesquihydrate 
  • Esomeprazole Magnesium Trihydrate and Dihydrate
  • Omeprazole Powder, Magnesium and Sodium
  • Esomeprazole Sodium
  • Pregabalin - IP
  • Fenofibrate

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.33%
1 Week
-1.74%
1 Month
+0.51%
3 Month
+22.32%
6 Month
+36.29%
1 Year
+100.23%
2 Year
+145.17%
5 Year
+868.88%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 52.28 25.00 23.31 33.19 3.06 12.25 9.86 33.63 36.22
Return on Capital Employed (%) 18.18 15.43 13.82 15.84 8.90 13.55 13.80 35.30 34.98
Return on Assets (%) 2.28 1.35 1.42 2.50 0.25 1.67 1.90 7.45 9.58

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 3 4 4 6 6 16 19 26 34
Non Curr. Liab. 5 5 10 11 14 7 8 10 12
Curr. Liab. 44 48 51 50 56 63 67 71 74
Minority Int.
Equity & Liab. 52 56 65 67 76 86 94 107 120
Non Curr. Assets 21 24 25 25 29 37 36 40 41
Curr. Assets 31 33 41 42 47 49 58 67 79
Misc. Exp. not W/O
Total Assets 52 56 65 67 76 86 94 107 120

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 61 80 96 106 99 107 112 156 167
Other Income 0 0 1 1 1 1 1 1 1
Total Income 61 80 97 107 100 108 113 156 169
Total Expenditure -55 -74 -91 -98 -94 -101 -105 -138 -148
PBIDT 6 6 6 8 6 7 8 18 21
Interest -3 -3 -3 -3 -3 -3 -3 -3 -3
Depreciation -2 -2 -2 -3 -3 -2 -3 -3 -3
Taxation 0 0 0 0 0 0 -1 -5 -3
Exceptional Items -1 -1
PAT 1 1 1 2 0 1 2 8 11

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 6 7 1 4 7 10 5 9 10
Cash Fr. Inv. -5 -4 -3 -3 -7 -8 -4 -5 -6
Cash Fr. Finan. -2 -3 2 -2 0 -2 0 -3 -3
Net Change 0 0 0 0 0 0 1 1 0
Cash & Cash Eqvt 1 1 1 1 1 1 1 2 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 73.28 73.45 73.60 73.79 73.79 73.79 74.04 74.15 74.15
Public 26.72 26.55 26.40 26.21 26.21 26.21 25.96 25.85 25.85
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 21 Jul 2021
Revocation Of Factory Closure Order
With reference to the captioned subject we are happy to inform you that the Company has received Extension of Revocation of Factory Closure Order for a further period of six months from Telangana State Pollution Control Board (TSPCB) orders issued dated 13.07.2021.

Further the Company is in full compliance with all the pollutions norms and is confident that it would be revoked permanently.
Mon, 12 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject we hereby inform you that the attached details of the share certificate is reported to have been lost by the shareholders of the Company.
This is for your information and record
Mon, 05 Jul 2021
Shareholding for the Period Ended June 30 2021
Everest Organics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Mon, 26 Jul 2021
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Stochastic Entering Oversold Zone From Above Stochastic Entering Oversold Zone From Above
Stochastic In Oversold Zone Stochastic In Oversold Zone
NR 4 NR 4

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%